NASDAQ:AKCA
Delisted
Akcea Therapeutics, Inc. Stock News
$18.17
+0 (+0%)
At Close: May 27, 2022
Akcea Announces Appointment of New Chief Financial Officer
11:00am, Monday, 18'th May 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief f
NEW YORK, NY / ACCESSWIRE / May 15, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
NEW YORK, NY / ACCESSWIRE / May 14, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
NEW YORK, NY / ACCESSWIRE / May 13, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)
12:00pm, Wednesday, 13'th May 2020
OTTAWA , May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (AKCA), today announced that it has concluded its negotiation with the pan-Canadian Pharmaceut
NEW YORK, NY / ACCESSWIRE / May 11, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Why Akcea (AKCA) Stock Might be a Great Pick
12:32pm, Monday, 11'th May 2020
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
NEW YORK, NY / ACCESSWIRE / May 9, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Xconomy: Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More
02:33pm, Friday, 08'th May 2020
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open
NEW YORK, NY / ACCESSWIRE / May 8, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
11:00am, Thursday, 07'th May 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human r
NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf
Needham Sticks to Their Buy Rating for Akcea Therapeutics Inc
05:58am, Wednesday, 06'th May 2020
Needham analyst Chad Messer reiterated a Buy rating on Akcea Therapeutics (NASDAQ:AKCA) Inc on Wednesday, setting a price target of $41, which is approximately 154.34% above the present share price of
Akcea Therapeutics, Inc. (AKCA) Q1 2020 Earnings Call Transcript
04:01am, Wednesday, 06'th May 2020
With me today are Damien McDevitt, our Chief Executive Officer; Kyle Jenne, our Chief Commercial Officer; and Alex Howarth, our Chief Operating Officer. As a reminder, this conference call includes f
